Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
Biostrata Ltd on behalf of Thermo
FOCUS DIAGNOSTICS, INC.

Sensitive Test Enables Early Diagnosis of Rheumatoid Arthritis

By Labmedica International staff writers
Posted on 14 Dec 2011
A highly sensitive and specific laboratory test enables the early diagnosis of rheumatoid arthritis (RA), which in turn allows for successful treatment of this autoimmune disease.

The new Anti-CCP hs (high sensitive) test is the most recent development in the area of anticitrullinated peptide antibody (ACPA) testing. This innovative enzyme immunoassay combines the advantages of mutated citrullinated vimentin (MCV) antibody detection (anti-MCV), with the power of modern peptide synthesis. It an effective tool for the rapid and precise routine diagnosis of suspected RA and the diagnosis of early rheumatoid arthritis.

In combination with medical history, clinical observations, and imaging techniques, serological tests like Anti-CCP hs are the basis for early diagnosis of RA. Early diagnosis is critical to patient outcomes because early, effective treatment can avert damage to the joints and maintain their function.

Orgentec Diagnostika (Mainz, Germany) developed the Anti-CCP hs test; it also develops and markets test systems for autoimmune diagnostics and serological tests for infectious disease. Orgentec has developed numerous highly specific ELISA test systems, immunoblot and immunofluorescence tests, the Alegria random access analyzer, and the rheumachec rapid test.

Related Links:
Orgentec Diagnostika


DIASYS DIAGNOSTIC SYSTEMS
KARL HECHT GMBH & CO KG
EUROIMMUN AG
WATERS CORPORATION

Channels

Genetic Tests

view channel
Image: Severe rheumatoid arthritis can destroy the joints and deform the wrist, finger and knuckle joints (Photo courtesy of Cedars-Sinai).

Gene Variants Predicts Rheumatoid Arthritis Disease Outcomes

Advances have been made in identifying genetic susceptibility loci for autoimmune diseases, but evidence is needed regarding their association with prognosis and treatment response. Certain genetic... Read more

Industry News

view channel

Main Factors Driving Revenue Growth in Clinical Chemistry Identified

According to a report by Kalorama Information (New York, NY, USA), overall growth in the clinical chemistry market will be modest, driven mainly by new tests and demographic changes, including an aging population and increasing number of people at risk of cardiovascular disease, such as those with hypertension, diabetes... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.